NK012

NK012 is a 'nanodevice' formulation of SN-38 (an irinotecan metabolite). NK012 is an SN-38-releasing nanodevice constructed by covalently attaching SN-38 to the block copolymer PEG-PGlu, followed by self-assembly of amphiphilic block copolymers in aqueous media.^{[1] [2]}

It has entered phase II clinical trials for triple-negative breast cancer and relapsed small cell lung cancer^[3].

References

1. ^ http://www.cancer.gov/drugdictionary/?CdrID=574615
2. ^ Sumitomo et al. (2008). "Novel SN-38–Incorporated Polymeric Micelle, NK012, Strongly Suppresses Renal Cancer Progression". http://cancerres.aacrjournals.org/content/68/6/1631.abstract. 
3. ^ http://clinicaltrials.gov/ct2/results?term=NK012

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.v · Categories: Experimental cancer drugs Antineoplastic and immunomodulating drug stubs Wikimedia Foundation. 2010. Игры ⚽ Нужно сделать НИР? Ubenimex NK2 homeobox 1 18+ © Academic, 2000-2024 Contact us: Technical Support, Advertising Dictionaries export, created on PHP, Joomla, Drupal, WordPress, MODx. Mark and share Search through all dictionaries Translate… Search Internet Share the article and excerpts Direct link … Do a right-click on the link above and select “Copy Link”